Patidegib - PellePharm

Alternative Names: FIN-5; IPI-926; Patidegib topical gel - PellePharm; Patidegib-hydrochloride; Saridegib; Saridegib-hydrochloride

Latest Information Update: 14 Dec 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Infinity Pharmaceuticals
Developer Infinity Pharmaceuticals; PellePharm
Class Antineoplastics; Small molecules; Veratrum alkaloids
Mechanism of Action SMO protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Chondrosarcoma; Basal cell nevus syndrome
New Molecular Entity Yes

Highest Development Phases

Phase II Basal cell cancer; Basal cell nevus syndrome
Discontinued Chondrosarcoma; Head and neck cancer; Myelofibrosis; Pancreatic cancer

Most Recent Events

20 Nov 2017 Patidegib receives Breakthrough Therapy status for Basal Cell Nevus Syndrome in USA
20 Nov 2017 Patidegib receives Orphan Drug status for Basal Cell Nevus Syndrome in USA
20 Nov 2017 PellePharm plans a phase III trial in Basal Cell Nevus Syndrome in USA in the first half of 2018

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.